 | |
| Clinical data | |
|---|---|
| Other names | RU-42633; Desmethylmifepristone; 17β-Hydroxy-11β-[4-(methylamino)phenyl]-17α-(prop-1-yn-1-yl)estra-4,9-dien-3-one |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C28H33NO2 |
| Molar mass | 415.577 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Metapristone (developmental code nameRU-42633; also known asdesmethylmifepristone) is the majormetabolite ofmifepristone (RU-486, RU-38486) and aselective progesterone receptor modulator (SPRM) which itself was never marketed.[1][2][3][4] It is formed from mifepristone in theliver by theenzymeCYP3A4 viamonodemethylation, and circulates at concentrations higher than those of mifepristone.[1][5] The metabolite retains partial but considerableaffinity for theprogesterone receptor (PR) and theglucocorticoid receptor (GR) (RBATooltip relative binding affinity = 21% and 61% of that of mifepristone for the human forms of these receptors, respectively).[6][1] On the basis of actions that are apparently independent of its hormonal activity, metapristone is being researched as a potentialcancermetastaticchemopreventive agent.[2][3][4]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
